Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer

(MedPage Today) -- SEOUL, South Korea -- Treatment with the bispecific antibody ubamatamab alone or in combination with the PD-1 inhibitor cemiplimab (Libtayo) appeared to be safe and demonstrated activity in patients with recurrent ovarian cancer...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news